These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24088135)

  • 1. Impact of biomarkers on clinical trial risk.
    Reid GG; Bin Yameen TA; Parker JL
    Pharmacogenomics; 2013 Oct; 14(13):1645-58. PubMed ID: 24088135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical perspectives of personalized healthcare in oncology.
    Hodgson DR; Wellings R; Harbron C
    N Biotechnol; 2012 Sep; 29(6):656-64. PubMed ID: 22426411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine.
    Zineh I; Huang SM
    Biomark Med; 2011 Dec; 5(6):705-13. PubMed ID: 22103607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An industry statistician's perspective on PHC drug development.
    Fridlyand J; Yeh RF; Mackey H; Bengtsson T; Delmar P; Spaniolo G; Lieberman G
    Contemp Clin Trials; 2013 Nov; 36(2):624-35. PubMed ID: 23648396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
    Chackalamannil S; Desai MC
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roadblocks preventing personalized medicine from reaching its potential.
    Cohen JP
    Biomark Med; 2015; 9(1):5-8. PubMed ID: 25605450
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
    Broich K; Weiergräber M; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size and threshold estimation for clinical trials with predictive biomarkers.
    Mackey HM; Bengtsson T
    Contemp Clin Trials; 2013 Nov; 36(2):664-72. PubMed ID: 24064355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma.
    Rubinger DA; Hollmann SS; Serdetchnaia V; Ernst DS; Parker JL
    Biomark Med; 2015; 9(1):13-23. PubMed ID: 25605452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use.
    Burns LC; Orsini L; L'italien G
    Value Health; 2013; 16(6 Suppl):S16-9. PubMed ID: 24034307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration.
    Agur Z; Elishmereni M; Kheifetz Y
    Wiley Interdiscip Rev Syst Biol Med; 2014; 6(3):239-53. PubMed ID: 24604755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteomics for biomarker development toward personalized medicine].
    Kondo T
    Rinsho Byori; 2012 Jul; 60(7):644-9. PubMed ID: 22973724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in T-cell therapy clinical trials.
    Lacey SF; Kalos M
    Cytotherapy; 2013 Jun; 15(6):632-40. PubMed ID: 23415917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Company Profile: AKESOgen, Inc.
    Bouzyk M; Boisjoli R
    Pharmacogenomics; 2012 Jul; 13(10):1115-8. PubMed ID: 22909201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic biomarker development.
    Bock C
    Epigenomics; 2009 Oct; 1(1):99-110. PubMed ID: 22122639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.